SGO

SONORO GOLD ANNOUNCES CLOSING OF SECOND TRANCHE OF NON-BROKERED PRIVATE PLACEMENT

Retrieved on: 
Tuesday, August 1, 2023
Minority, TSX Venture Exchange, SGO, MI, Private placement, Offering, Policy, Multilateral, Security (finance), Unit

Pursuant to the Private Placement, the Company has issued 20,007,920 units at a price of C$0.10 per unit, in two tranches for aggregate gross proceeds of C$2,000,792, subject to approval of the TSX Venture Exchange (the "TSXV").

Key Points: 
  • Pursuant to the Private Placement, the Company has issued 20,007,920 units at a price of C$0.10 per unit, in two tranches for aggregate gross proceeds of C$2,000,792, subject to approval of the TSX Venture Exchange (the "TSXV").
  • Each Unit consists of one Sonoro common share and one common share purchase warrant.
  • Each warrant entitles the holder thereof to purchase one additional Sonoro common share for a period of two years from the closing of the private placement at an exercise price of C$0.15 per share.
  • All securities issued and issuable in connection with the second tranche are subject to a 4-month plus one day hold period ending December 2, 2023.

Jemperli (dostarlimab-gxly) plus chemotherapy approved in the US as the first new frontline treatment option in decades for dMMR/MSI-H primary advanced or recurrent endometrial cancer

Retrieved on: 
Monday, July 31, 2023
Oncology, FDA, Health, Clinical Trials, Pharmaceutical, Biotechnology, Orbis, GSK, Priority review, US Foods, Risk, Prescription Drug User Fee Act, Radiation, Society, SGO, Senior, Diarrhea, Society of Gynecologic Oncology, The New England Journal of Medicine, ESMO, European Medicines Agency, Clinical trial, Paclitaxel, Hope, Gynecologic Oncology (journal), Part, Carboplatin, Hypothyroidism, European Society for Medical Oncology, PFS, Rash, Hypertension, GSK plc, Endometrial cancer, HIV disease progression rates, MD, Patient, Division, FORCE, Annual general meeting, Washington University School of Medicine, United Kingdom, European Society of Gynaecological Oncology, ITT, Death, III, News, Food, Safety, Pharmaceutical industry, Dostarlimab

Hesham Abdullah, Senior Vice President, Global Head of Oncology Development, GSK, said: “Today’s expanded approval of Jemperli redefines the treatment landscape for patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer.

Key Points: 
  • Hesham Abdullah, Senior Vice President, Global Head of Oncology Development, GSK, said: “Today’s expanded approval of Jemperli redefines the treatment landscape for patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer.
  • Until now, chemotherapy alone has been the standard of care with many patients experiencing disease progression.
  • These results and today’s approval underscore our belief in the potential for Jemperli to transform cancer treatment as a backbone immuno-oncology therapy.”
    With this approval, Jemperli is now indicated earlier in treatment in combination with chemotherapy for patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer.
  • The most common treatment-emergent adverse events (≥ 20%) in patients receiving Jemperli plus chemotherapy were rash, diarrhea, hypothyroidism and hypertension.

Sonoro Gold Corp. Presents in Red Cloud's Virtual Webinar Series

Retrieved on: 
Tuesday, July 11, 2023
Cloud, SGO, Gold, Red Cloud, Q&A, Web conferencing

Toronto, Ontario--(Newsfile Corp. - July 11, 2023) - Sonoro Gold Corp. (TSXV: SGO) is pleased to announce that the company is presenting a live virtual corporate update hosted by Red Cloud Financial Services on July 13th, 2023 at 11:00 ET.

Key Points: 
  • Toronto, Ontario--(Newsfile Corp. - July 11, 2023) - Sonoro Gold Corp. (TSXV: SGO) is pleased to announce that the company is presenting a live virtual corporate update hosted by Red Cloud Financial Services on July 13th, 2023 at 11:00 ET.
  • We invite our shareholders, and all interested parties to register for the webinar and participate in the live Q&A session at the end of the presentation moderated by Red Cloud.
  • The replay will be emailed out to all webinar registrants proceeding the event and will also be available on the Red Cloud website.
  • For more information and to register: https://redcloudfs.com/rcwebinar-sgo/
    The Webinar will focus on new gold mineralized targets as potential resource expansion in the northwestern region of the Cerro Caliche concession.

SONORO REPORTS GOLD MINERALIZED TARGETS IN NORTHWEST REGION OF CERRO CALICHE AS POTENTIAL RESOURCE EXPANSION

Retrieved on: 
Monday, July 10, 2023
Plata, GPS, SGO, Vein, Chemex Coffeemaker, Silver, Veta, Talus, QA/QC, Cerro, Mylonite, Corridor, Gold, Projection, Soil, Rincon, National instrument, Mining, National Instrument 43-101, Acid, Mineral resource estimation, Hand, ICP, News, Economics, Laramide orogeny, Rare-earth element, Uranium mining, Limestone, Sarmiento Formation

VANCOUVER, Canada, July 10, 2023 (GLOBE NEWSWIRE) -- Sonoro Gold Corp. (TSXV: SGO | OTCQB: SMOFF | FRA: 23SP) (“Sonoro” or the “Company”) is pleased to report oxide mineralized targets identified for resource expansion at the Company’s Cerro Caliche gold project, located in Sonora State, Mexico.

Key Points: 
  • VANCOUVER, Canada, July 10, 2023 (GLOBE NEWSWIRE) -- Sonoro Gold Corp. (TSXV: SGO | OTCQB: SMOFF | FRA: 23SP) (“Sonoro” or the “Company”) is pleased to report oxide mineralized targets identified for resource expansion at the Company’s Cerro Caliche gold project, located in Sonora State, Mexico.
  • Exploration to date at Cerro Caliche has identified a wide area of mineralized low-sulfidation epithermal vein structures and the presence of multiple northwest trending gold mineralized zones along trend and at near surface.
  • Assay results with data resolution from surface sampling, together with geologic mapping and adjacent drill holes, suggest the potential expansion of the project’s oxide gold mineralized zones and resource.
  • Oxide gold mineralized targets within the Northwestern Corridors Area are of shallow gold mineralization in near surface environments.

SONORO ANNOUNCES RESULTS OF ANNUAL GENERAL MEETING

Retrieved on: 
Wednesday, July 5, 2023
Plata, Minority, TSX Venture Exchange, SGO, Professional Football Compensation Committee, University, MI, S.A, Glamis Gold, AGM, Meeting, Exploration, Eldorado Gold, Colorado School of Mines, Pediment, La Colorada, Student, Gold, Metallurgy, Offering, Mining, Corporation, Guanajuato, Mineral economics, Policy, Multilateral, Corporate development, Security (finance), Management, Operation

VANCOUVER, Canada, July 05, 2023 (GLOBE NEWSWIRE) -- Sonoro Gold Corp., (TSXV: SGO | OTCQB: SMOFF | FRA: 23SP), (“Sonoro” and the “Company”) announces the results of its Annual General Meeting of Shareholders (the “Meeting”) held June 29, 2023, in Vancouver, BC.

Key Points: 
  • VANCOUVER, Canada, July 05, 2023 (GLOBE NEWSWIRE) -- Sonoro Gold Corp., (TSXV: SGO | OTCQB: SMOFF | FRA: 23SP), (“Sonoro” and the “Company”) announces the results of its Annual General Meeting of Shareholders (the “Meeting”) held June 29, 2023, in Vancouver, BC.
  • The shareholders voted to re-elect John M. Darch, Kenneth MacLeod, Stephen Kenwood, James Taylor and Curtis Turner to serve as directors of the Company until the next annual meeting of the shareholders.
  • Following the Meeting, the Board appointed Kenneth MacLeod, Stephen Kenwood and Curtis Turner to its Audit and Compensation Committees.
  • Each Unit will be composed of one Sonoro common share and one common share purchase warrant.

SONORO GOLD ANNOUNCES CLOSING OF FIRST TRANCHE OF NON-BROKERED PRIVATE PLACEMENT

Retrieved on: 
Tuesday, June 20, 2023
Minority, TSX Venture Exchange, SGO, MI, Offering, Policy, Multilateral, Security (finance), Unit

Each Unit consists of one Sonoro common share and one common share purchase warrant.

Key Points: 
  • Each Unit consists of one Sonoro common share and one common share purchase warrant.
  • Each warrant entitles the holder thereof to purchase one additional Sonoro common share for a period of two years from the closing of the private placement at an exercise price of C$0.15 per share.
  • All securities issued and issuable in connection with the First Tranche are subject to a 4-month plus one day hold period ending October 21, 2023.
  • In connection with the First Tranche, the Company paid $959.00 in Finder’s fees and issued 9,590 in non-transferable Finder’s Warrants.

Move4Her Returns Empowering Participants in the Fight to Eradicate Gynecologic Cancers

Retrieved on: 
Thursday, June 15, 2023
Society, SGO, Education, Vulvar cancer, FWC, National Press Club (United States), Press club, Gynecologic Oncology (journal), Research, Movement, EMLL 55th Anniversary Show, Organization, Society of Gynecologic Oncology, MD, Cancer, Diagnosis, Health, Message, Birth control

CHICAGO, June 15, 2023 /PRNewswire/ -- The Foundation for Women's Cancer (FWC) is pleased to announce the return of Move4Her, now bigger and better than ever! Embarking on its fourth consecutive year, Move4Her stands at the forefront of the FWC's mission to power research, awareness and education surrounding the five gynecologic (gyn) cancers – cervical, ovarian, uterine/endometrial, vaginal, and vulvar cancer.

Key Points: 
  • Embarking on its fourth consecutive year, Move4Her stands at the forefront of the FWC's mission to power research, awareness and education surrounding the five gynecologic (gyn) cancers – cervical, ovarian, uterine/endometrial, vaginal, and vulvar cancer.
  • Move4Her encourages participants to dedicate five minutes each day to their fitness and fundraising mission.
  • Taking steps to protect your health, and to connect with others by sharing stories and experiences, Move4Her participants will power a much-needed movement.
  • Throughout the year new tools and resources will be released to support individuals, teams and local organizations participating in Move4Her.

SONORO GOLD ANNOUNCES $3 MILLION PRIVATE PLACEMENT

Retrieved on: 
Wednesday, May 3, 2023
Unit, TSX Venture Exchange, SGO, Economics, IS, Gold, Offering, NEWS, Cryptocurrency, Uranium mining

VANCOUVER, Canada, May 03, 2023 (GLOBE NEWSWIRE) -- Sonoro Gold Corp. (TSXV: SGO | OTCQB: SMOFF | FRA: 23SP) (“Sonoro” or the “Company”) is pleased to announce that it will undertake a non-brokered private placement offering (the "Offering") consisting of up to 30,000,000 units (the “Units”) at a price of C$0.10 per Unit, for gross proceeds of up to C$3,000,000.  

Key Points: 
  • Each Unit will be composed of one Sonoro common share and one common share purchase warrant.
  • Each warrant will entitle the holder thereof to purchase one additional Sonoro common share for a period of two years from the closing of the private placement at an exercise price of C$0.15 per share.
  • All securities issued and issuable in connection with the Offering will be subject to a 4-month hold period in Canada from the closing date.
  • Increasing the average grade at the El Colorado and Guadalupe vein zones may enhance the overall economics of the project.”

ImmunoGen Reports Recent Progress and First Quarter 2023 Financial Results

Retrieved on: 
Friday, April 28, 2023
Biotechnology, General Health, Health, Pharmaceutical, Oncology, Biologics license application, Capital expenditure, Society, SGO, ASH, Senior, Progression-free survival, Marketing, European Medicines Agency, Survival, Clinical trial, Cancer, Gynecologic Oncology (journal), György Enyedi (geographer), Society of Gynecologic Oncology, NSCLC, Lung cancer, PFS, Mirvetuximab soravtansine, Gilead, Eli Lilly, EMA, Acute myeloid leukemia, PROC, AML, Azacitidine, PIN, Huadong Medicine, Pharmakon—Danish College of Pharmacy Practice, Patient, National Medical Products Administration, Annual general meeting, ImmunoGen, Vertex Pharmaceuticals, ADC, Spacecraft, MAA, Research, FDA, Ovarian cancer, LP, BLA, NMPA, Medicine, Vaccine, Management, Pharmaceutical industry, Mobile phone, Vertex

(Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today reviewed recent progress in the business and reported financial results for the quarter ended March 31, 2023.

Key Points: 
  • (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today reviewed recent progress in the business and reported financial results for the quarter ended March 31, 2023.
  • Research and development expenses rose to $51.6 million for the quarter ended March 31, 2023 compared to $44.3 million for the quarter ended March 31, 2022.
  • Selling, general and administrative expenses were $40.0 million for the quarter ended March 31, 2023 compared to $16.6 million for the quarter ended March 31, 2022.
  • ImmunoGen had $201.2 million in cash and cash equivalents as of March 31, 2023, compared with $275.1 million as of December 31, 2022.

Sonoro Gold: A High-Potential Investment Opportunity for Gold, CEO Clips Video

Retrieved on: 
Tuesday, April 4, 2023
SGO, Gold, Mining

Vancouver, British Columbia--(Newsfile Corp. - April 4, 2023) - Sonoro Gold Corp. (TSXV: SGO) (OTCQB: SMOFF) - is rapidly developing its Cerro Caliche Gold Project in northern Mexico, with over 59,000m of drilling and over 420,000 ounces of gold resources contained within the pit shells and the potential for up to an additional 275,000 ounces of gold mineralization in the zones surrounding the pit shells which have been identified by drilling.

Key Points: 
  • Vancouver, British Columbia--(Newsfile Corp. - April 4, 2023) - Sonoro Gold Corp. (TSXV: SGO) (OTCQB: SMOFF) - is rapidly developing its Cerro Caliche Gold Project in northern Mexico, with over 59,000m of drilling and over 420,000 ounces of gold resources contained within the pit shells and the potential for up to an additional 275,000 ounces of gold mineralization in the zones surrounding the pit shells which have been identified by drilling.
  • This resource area represents less than 30% of the known mineralized zones on the property.
  • The company is focused on bringing the project to production within the next 12 months, expanding its mineral resources and generating revenue from gold mining.